Glenmark Pharmaceuticals Inc. has launched Clindamycin Phosphate Foam, 1%, which is equivalent to Mylan's Evoclin Foam, with an annual market of approximately $5.8 million. This product enhances Glenmark's presence in the dermatology therapeutic area.